{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:55:07Z","timestamp":1792799707121,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vaccine.2026.128692","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:57:32Z","timestamp":1778947052000},"page":"128692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunogenicity of 2 versus 3 dose HPV vaccination by HIV infection status in Eswatini"],"prefix":"10.1016","volume":"85","author":[{"given":"Harriet","family":"Nuwagaba-Biribonwoha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xolisile","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Zerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence A.","family":"Anabwani-Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Zech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomxolisi","family":"Mabuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njabuliso Michael","family":"Lukhele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Fayorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Sahabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejoice","family":"Nkambule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa M.","family":"El-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine J.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2026.128692_bb0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.15585\/mmwr.mm7012a2","article-title":"Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine - United States, 2003-2018","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128692_bb0010","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128692_bb0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128692_bb0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128692_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2026.128692_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103290","article-title":"Global HPV vaccination programs and coverage rates: a systematic review","volume":"84","author":"Han","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128692_bb0035","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-4035","article-title":"Three-year follow-up of 2-dose versus 3-dose HPV vaccine","volume":"147","author":"Bornstein","year":"2021","journal-title":"Pediatrics"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128692_bb0040","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128692_bb0045","article-title":"Safety and immunogenicity of the Nonavalent human papillomavirus vaccine in women living with HIV","volume":"12","author":"Hidalgo-Tenorio","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128692_bb0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128692_bb0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/vaccines8040618","article-title":"Immunogenicity of alternative dosing schedules for HPV vaccines among adolescent girls and young women: a systematic review and meta-analysis","volume":"8","author":"Secor","year":"2020","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128692_bb0060","article-title":"Efficacy and durability of immune response after receipt of HPV vaccines in people living with HIV","volume":"11","author":"Losada","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128692_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101585","article-title":"Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: a systematic review and meta-analysis","volume":"52","author":"Staadegaard","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128692_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-83727-7","article-title":"Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"11","author":"Zizza","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128692_bb0075","article-title":"Comprehensive evaluation of prophylactic HPV vaccines: a systematic review and meta-analysis of efficacy, safety, and immunogenicity in males and females","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128692_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003931","article-title":"Understanding human papillomavirus vaccine response and efficacy in people living with HIV: a systematic mixed studies review and meta-analysis","volume":"4","author":"Akumbom","year":"2024","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.vaccine.2026.128692_bb0085","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128692_bb0090","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update)","volume":"97","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128692_bb0095","series-title":"Gardasil 9 Packet Insert","author":"Merck Sharp and Dohme LLC.","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128692_bb0100","author":"World Population Review"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128692_bb0105","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.128692_bb0110","series-title":"World Health Organisation(WHO). HIV and cancer","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128692_bb0115","series-title":"National Cancer Registry","author":"Eswatini Ministry of Health","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128692_bb0120","series-title":"World Health Organisation (WHO), US President's Emergency Plan for AIDS Relief (PEPFAR). Eswatini Integrated HIV Management Guidelines, 2022","author":"Eswatini Ministry of Health","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128692_bb0125","series-title":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events","author":"Division of AIDS (DAIDS)","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128692_bb0130","author":"Merck","year":"2015"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128692_bb0135","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128692_bb0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/10543400600719251","article-title":"Statistical considerations for noninferiority\/equivalence trials in vaccine development","volume":"16","author":"Wang","year":"2006","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.vaccine.2026.128692_bb0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pvr.2017.03.002","article-title":"Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - a combined analysis of five phase III clinical trials","volume":"3","author":"Petersen","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2026.128692_bb0150","series-title":"The path that ends AIDS: UNAIDS Global AIDS Update 2023","author":"Joint United Nations Program on HIV\/AIDS","year":"2023"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128692_bb0155","doi-asserted-by":"crossref","first-page":"e2153","DOI":"10.1016\/S2214-109X(25)00376-6","article-title":"Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis","volume":"13","author":"Benard","year":"2025","journal-title":"Lancet Glob Health"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2026.128692_bb0160","doi-asserted-by":"crossref","first-page":"F32","DOI":"10.1016\/j.vaccine.2012.07.092","article-title":"The burden of human papillomavirus infections and related diseases in sub-Saharan Africa","volume":"31","author":"De Vuyst","year":"2013","journal-title":"Vaccine"},{"issue":"10108","key":"10.1016\/j.vaccine.2026.128692_bb0165","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:28:15Z","timestamp":1783290495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S0264410X26005001"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128692","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of 2 versus 3 dose HPV vaccination by HIV infection status in Eswatini","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128692"}}